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Background
Dose selection for immuno-oncology (I-O) treatments
presents unique challenges and opportunities. Surrogate
efficacy endpoints in early clinical studies (typically
objective anti-tumor response) may not fully represent
the potential for improved overall survival in pivotal
trials, complicating selection of a Phase III dose and
schedule. Conversely, the immune-stimulating mechan-
ism of action of I-O agents, such as nivolumab, a pro-
grammed death-1 (PD-1) immune checkpoint inhibitor,
may support one dosing regimen across multiple tumor
types. Here, we describe an integrated approach to iden-
tify the most suitable monotherapy dose for nivolumab
across solid tumor indications.
Methods
The dose was selected primarily based on nivolumab
anti-tumor activity and safety data from a large Phase Ib
open-label, dose-escalation study of nivolumab in 306
patients (pts) with advanced or recurrent malignancies
including a total of 270 pts with melanoma (MEL), non-
small cell lung cancer (NSCLC), or renal cell carcinoma
(RCC) (CA209003) treated at doses from 0.1 to 10 mg/kg
every two weeks (Q2W). In total, 306 pts were evaluable
for safety across 5 tumor types, and 270 for efficacy in
the select tumor types. Additionally, an integrated quan-
titative analysis was performed to estimate the relation-
ships of dose-exposure response to biomarkers (receptor
occupancy [RO]), safety (adverse events [AE] leading to
discontinuation), and efficacy (objective response rate
[ORR], progression free survival [PFS], and tumor growth
dynamics).
Results
Nivolumab was well tolerated up to the highest dose of
10 mg/kg administered in the dose escalation study,
without identifying a maximum tolerated dose. The nat-
ure, frequency, and severity of any causality and treat-
ment-related safety events were similar across tumor
types and dose levels, as were probabilities of AEs lead-
ing to discontinuation. ORRs were similar between 1
and 10 mg/kg in MEL and RCC, however higher ORRs
were observed in NSCLC at 3 and 10 mg/kg doses ver-
sus 1 mg/kg (Table 1). Peripheral RO was saturated at
≥0.3 mg/kg dose. In exposure-response analysis, a trend
was observed for each tumor type but appeared to
Bristol-Myers Squibb, Princeton, NJ, United States
Table 1
MEL (N=107) NSCLC (N=129) RCC (N-34)
Dose (mg/kg) ORR % (n/N) PFS 24 wks, % ORR % (n/N) PFS 24 wks, % ORR % (n/N) PFS 24 wks, %
0.1 35 (6/17) 41 - - - -
0.3 28 (5/18) 35 - - - -
1 31 (11/35) 51 3 (1/33) 26 28 (5/18) 50
3 41 (7/17) 55 24 (9/37) 40 - -
10 20 (4/20) 35 20 (12/59) 33 31 (5/16) 67
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plateau at ≥3 mg/kg Q2W. While the exposure-response
for tumor shrinkage was relatively flat, tumor progres-
sion rate tended to decrease with increasing exposure.
Conclusions
The selected monotherapy dose of 3 mg/kg Q2W pro-
vides for unified dosing of nivolumab across the clinical
development program. The approach taken, integrating
dose-exposure responses with safety and efficacy data,
represents a means to make rational dose selections for
I-O agents.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P141
Cite this article as: Agrawal et al.: Nivolumab dose selection: challenges,
opportunities and lessons learned for cancer immunotherapy. Journal
for ImmunoTherapy of Cancer 2015 3(Suppl 2):P141.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Agrawal et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P141
http://www.immunotherapyofcancer.org/content/3/S2/P141
Page 2 of 2
